非HDL‐C在2型糖尿病合并心血管疾病的研究进展

doi:10.12677/acm.2026.1682929

期刊菜单

非HDL‐C在2型糖尿病合并心血管疾病的研究进展
Research Progress of Non-HDL-C in Type 2 Diabetes Mellitus Complicated with Cardiovascular Disease

DOI: 10.12677/acm.2026.1682929, PDF,
作者: 谢子琴：绍兴大学医学院，浙江绍兴；胡素佩^*：宁波市第二医院科研科，浙江宁波
关键词: 非高密度脂蛋白胆固醇；2型糖尿病；心血管疾病；动脉粥样硬化性心血管疾病；血脂异常；Non‑High‑Density Lipoprotein Cholesterol； Type 2 Diabetes Mellitus； Cardiovascular Disease； Atherosclerotic Cardiovascular Disease； Dyslipidemia

摘要: 血脂异常是2型糖尿病常见的代谢紊乱之一，显著增加糖尿病患者发生心血管疾病的风险。心血管疾病是糖尿病患者发病和死亡率的主要原因。非高密度脂蛋白胆固醇(非HDL‐C)是指除高密度脂蛋白胆固醇(HDL-C)以外其他脂蛋白中含有胆固醇的总和。近年来，非HDL‐C已被国内外权威指南推荐作为ASCVD风险评估和降低ASCVD风险的重要血脂干预靶点，非HDL-C在糖尿病并发症管理中的重要性也越来越得到关注，并被最新的中国糖尿病患者脂质管理专家共识确立为与低密度脂蛋白胆固醇(LDL-C)并列的主要降脂靶点。本文综述非HDL‐C在T2DM合并心血管疾病中的研究进展。

Abstract: Dyslipidemia is one of the common metabolic disorders in type 2 diabetes mellitus (T2DM), significantly increasing the risk of cardiovascular disease (CVD) in diabetic patients. CVD is the leading cause of morbidity and mortality in individuals with diabetes. Non‑high‑density lipoprotein cholesterol (non‑HDL‑C) refers to the total cholesterol content carried by all lipoproteins other than high‑density lipoprotein cholesterol (HDL‑C). In recent years, non‑HDL‑C has been recommended by major domestic and international guidelines as an important lipid intervention target for atherosclerotic cardiovascular disease (ASCVD) risk assessment and risk reduction. The importance of non‑HDL‑C in the management of diabetic complications has also gained increasing attention, and it has been established as a primary lipid‑lowering target on par with low‑density lipoprotein cholesterol (LDL‑C) in the latest Chinese expert consensus on lipid management in diabetic patients. This article reviews the research progress on non‑HDL‑C in T2DM complicated with CVD.

文章引用：谢子琴, 胡素佩. 非HDL‐C在2型糖尿病合并心血管疾病的研究进展[J]. 临床医学进展, 2026, 16(8): 1510-1518. https://doi.org/10.12677/acm.2026.1682929

参考文献

[1]	Zhou, Y.C., Liu, J.m., Zhao, Z.P., Zhou, M. and Ng, M. (2025) The National and Provincial Prevalence and Non-Fatal Burdens of Diabetes in China from 2005 to 2023 with Projections of Prevalence to 2050. Military Medical Research, 12, Article No. 28. https://doi.org/10.1186/s40779-025-00615-1
[2]	刘靖, 周翔海. 冠心病合并2型糖尿病患者的血糖管理专家共识[J]. 中国循环杂志, 2024, 39(4): 342-352.
[3]	Katsi, V., Argyriou, N., Fragoulis, C. and Tsioufis, K. (2025) The Role of Non-HDL Cholesterol and Apolipoprotein B in Cardiovascular Disease: A Comprehensive Review. Journal of Cardiovascular Development and Disease, 12, Article 256. https://doi.org/10.3390/jcdd12070256
[4]	Contois, J.H., Langlois, M.R., Cobbaert, C. and Sniderman, A.D. (2023) Standardization of Apolipoprotein B, LDL‐Cholesterol, and Non‐HDL‐Cholesterol. Journal of the American Heart Association, 12, e030405. https://doi.org/10.1161/jaha.123.030405
[5]	中国中西医结合学会检验医学专业委员会. 非传统血脂指标与动脉粥样硬化性心血管疾病风险管理中国专家共识[J]. 中华预防医学杂志, 2022, 56(4): 405-421.
[6]	Arsenault, B.J., Rana, J.S., Stroes, E.S.G., Després, J., Shah, P.K., Kastelein, J.J.P., et al. (2009) Beyond Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology, 55, 35-41. https://doi.org/10.1016/j.jacc.2009.07.057
[7]	Wilkins, J.T., Ning, H., Allen, N.B., Zheutlin, A., Shah, N.S., Feinstein, M.J., et al. (2024) Prediction of Cumulative Exposure to Atherogenic Lipids during Early Adulthood. Journal of the American College of Cardiology, 84, 961-973. https://doi.org/10.1016/j.jacc.2024.05.070
[8]	O’Brien, R.C., Gonzalez-Santos, L.E., Tomlinson, B., Hussein, Z., Lim, S., Nawawi, H., et al. (2026) Importance and Management of Non-High-Density Lipoprotein Cholesterol in Dyslipidemia Treatment. JACC: Asia, 6, 403-417. https://doi.org/10.1016/j.jacasi.2025.12.024
[9]	Helgadottir, A., Gretarsdottir, S., Thorleifsson, G., Hjartarson, E., Sigurdsson, A., Magnusdottir, A., et al. (2016) Variants with Large Effects on Blood Lipids and the Role of Cholesterol and Triglycerides in Coronary Disease. Nature Genetics, 48, 634-639. https://doi.org/10.1038/ng.3561
[10]	中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 非HDL-C与心血管疾病风险关系及临床管理专家共识[J]. 中华心血管病杂志, 2026, 54(5): 518-527.
[11]	Li, S., Liu, Z., Joseph, P., Hu, B., Yin, L., Tse, L.A., et al. (2022) Modifiable Risk Factors Associated with Cardiovascular Disease and Mortality in China: A PURE Substudy. European Heart Journal, 43, 2852-2863. https://doi.org/10.1093/eurheartj/ehac268
[12]	Yang, Z., Zhou, P., Fan, F., Hao, Y., Zhao, W., Wang, Z., et al. (2025) A Simple Score, CKM2S2-BAG, to Predict Cardiovascular Risk with Cardiovascular-Kidney-Metabolic Health Metrics. iScience, 28, Article 112780. https://doi.org/10.1016/j.isci.2025.112780
[13]	王增武, 刘静, 李建军, 等. 中国血脂管理指南(2023年) [J]. 中国循环杂志, 2023, 38(3): 237-271.
[14]	Score2-Op Working Group and Esc Cardiovascular Risk Collaboration (2021) SCORE2-OP Risk Prediction Algorithms: Estimating Incident Cardiovascular Event Risk in Older Persons in Four Geographical Risk Regions. European Heart Journal, 42, 2455-2467.
[15]	Mach, F., Koskinas, K.C., Roeters van Lennep, J.E., Tokgözoğlu, L., Badimon, L., Baigent, C., et al. (2025) 2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias. Atherosclerosis, 409, Article 120479. https://doi.org/10.1016/j.atherosclerosis.2025.120479
[16]	Taskinen, M. and Borén, J. (2015) New Insights into the Pathophysiology of Dyslipidemia in Type 2 Diabetes. Atherosclerosis, 239, 483-495. https://doi.org/10.1016/j.atherosclerosis.2015.01.039
[17]	Ray, K.K., Leiter, L.A., Müller‐Wieland, D., Cariou, B., Colhoun, H.M., Henry, R.R., et al. (2018) Alirocumab vs Usual Lipid‐Lowering Care as Add‐on to Statin Therapy in Individuals with Type 2 Diabetes and Mixed Dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA Randomized Trial. Diabetes, Obesity and Metabolism, 20, 1479-1489. https://doi.org/10.1111/dom.13257
[18]	Seo, I.H., Son, D.H., Lee, H.S. and Lee, Y. (2022) Non-HDL Cholesterol as a Predictor for Incident Type 2 Diabetes in Community-Dwelling Adults: Longitudinal Findings over 12 Years. Translational Research, 243, 52-59. https://doi.org/10.1016/j.trsl.2021.12.008
[19]	Han, M., Shen, Y., Guo, X., Hong, C., Ji, X., Guo, H., et al. (2025) Association between Non-High-Density Lipoprotein Cholesterol and Type 2 Diabetes: A Systematic Review and Meta-Analysis of Cohort Studies. Endocrine Journal, 72, 43-51. https://doi.org/10.1507/endocrj.ej24-0189
[20]	Gornik, H.L., Aronow, H.D., Goodney, P.P., Arya, S., Brewster, L.P., Byrd, L., et al. (2024) 2024 ACC/AHA/AACVPR/ APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 149, e1313-e1410. https://doi.org/10.1161/cir.0000000000001251
[21]	Sheng, G., Kuang, M., Yang, R., Zhong, Y., Zhang, S. and Zou, Y. (2022) Evaluation of the Value of Conventional and Unconventional Lipid Parameters for Predicting the Risk of Diabetes in a Non-Diabetic Population. Journal of Translational Medicine, 20, Article No. 266. https://doi.org/10.1186/s12967-022-03470-z
[22]	Yin, J., Fu, X., Luo, Y., Leng, Y., Ao, L. and Xie, C. (2024) A Narrative Review of Diabetic Macroangiopathy: From Molecular Mechanism to Therapeutic Approaches. Diabetes Therapy, 15, 585-609. https://doi.org/10.1007/s13300-024-01532-7
[23]	Fan, J. and Watanabe, T. (2022) Atherosclerosis: Known and Unknown. Pathology International, 72, 151-160. https://doi.org/10.1111/pin.13202
[24]	Johannesen, C.D.L., Mortensen, M.B., Langsted, A. and Nordestgaard, B.G. (2021) Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk than LDL Cholesterol in Statin-Treated Patients. Journal of the American College of Cardiology, 77, 1439-1450. https://doi.org/10.1016/j.jacc.2021.01.027
[25]	Brunner, F.J., Waldeyer, C., Ojeda, F., Salomaa, V., Kee, F., Sans, S., et al. (2019) Application of Non-HDL Cholesterol for Population-Based Cardiovascular Risk Stratification: Results from the Multinational Cardiovascular Risk Consortium. The Lancet, 394, 2173-2183. https://doi.org/10.1016/s0140-6736(19)32519-x
[26]	Murakami, T., Kato, S., Shigeeda, T., Itoh, H., Komuro, I., Takeuchi, M., et al. (2021) Intensive Treat-to-Target Statin Therapy and Severity of Diabetic Retinopathy Complicated by Hypercholesterolaemia. Eye, 35, 2221-2228. https://doi.org/10.1038/s41433-020-01202-5
[27]	Malave, H., Castro, M., Burkle, J., Voros, S., Dayspring, T., Honigberg, R., et al. (2012) Evaluation of Low-Density Lipoprotein Particle Number Distribution in Patients with Type 2 Diabetes Mellitus with Low-Density Lipoprotein Cholesterol < 50 Mg/Dl and Non-High-Density Lipoprotein Cholesterol < 80 Mg/Dl. The American Journal of Cardiology, 110, 662-665. https://doi.org/10.1016/j.amjcard.2012.04.046
[28]	Cho, Y.K. and Jung, C.H. (2021) HDL-C and Cardiovascular Risk: You Don’t Need to Worry about Extremely High HDL-C Levels. Journal of Lipid and Atherosclerosis, 10, 57-61. https://doi.org/10.12997/jla.2021.10.1.57
[29]	Madsen, C.M., Varbo, A. and Nordestgaard, B.G. (2017) Extreme High High-Density Lipoprotein Cholesterol Is Paradoxically Associated with High Mortality in Men and Women: Two Prospective Cohort Studies. European Heart Journal, 38, 2478-2486. https://doi.org/10.1093/eurheartj/ehx163
[30]	Mach, F., Baigent, C., Catapano, A.L., et al. (2020) 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. European Heart Journal, 41, 111‐188.

为你推荐

友情链接